
Gene Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5521040/publications.pdf Version: 2024-02-01



GENELIN

#	Article	IF	CITATIONS
1	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Research, 2018, 78, 1003-1016.	0.4	269
2	Pediatric tolerogenic DCs expressing CD4 and immunoglobulinâ€like transcript receptor (ILT)â€4 secrete ILâ€10 in response to Fc and adenosine. European Journal of Immunology, 2018, 48, 482-491.	1.6	15
3	Induction of antiinflammatory purinergic signaling in activated human iNKT cells. JCI Insight, 2018, 3, .	2.3	14
4	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	2.5	38
5	Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood, 2013, 121, 3329-3334.	0.6	87
6	NF-κB Is Activated in CD4+ iNKT Cells by Sickle Cell Disease and Mediates Rapid Induction of Adenosine A2A Receptors. PLoS ONE, 2013, 8, e74664.	1.1	28
7	NF-ήB Activation Mediates Induction Of Anti-Inflammatory Adenosine A2A Receptors In iNKT Cells Of Sickle Cell Patients During Vaso-Occlusive Episodes and Upon Activation Of Cultured Human iNKT Cells. Blood, 2013, 122, 975-975.	0.6	0
8	Human Sickle Cell Disease Increases Numbers and Activation Of Peripheral Blood Myeloid Dendritic Cells, Monocytes, and Neutrophils. Blood, 2013, 122, 1033-1033.	0.6	0
9	The Role Of NF-κB In The Activation Of Human iNKT Cells In Sickle Cell Disease Patients and In Vitro. Blood, 2013, 122, 2291-2291.	0.6	0
10	Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease. Blood, 2011, 118, 849-849.	0.6	0